VetResQ Adds Advanced, First-In-Kind Blood Purification Treatment of Inflammatory Toxins to the U.S. Veterinary Market. Debuts at American College of Veterinary Emergency and Critical Care Post-Graduate Review Conference.

MONMOUTH JUNCTION, N.J., Jan. 20, 2017 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the marketing launch and commercial availability of the VetResQ™ sorbent cartridge for the United States veterinary market. VetResQ is a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication.


VetResQ is being showcased at the American College of Veterinary Emergency and Critical Care (ACVECC) Post-Graduate Review Course on January 20-21, 2017 in Honolulu, Hawaii, where CytoSorbents is one of the main sponsors and will have a prominent booth position to talk to interested parties. The ACVECC conference is held in conjunction with the 46th Society of Critical Care Medicine Congress (January 21-25, 2017), where CytoSorbents is also an exhibitor (Booth #606).

Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, “The VetResQ adsorber provides a new and unique treatment for severe inflammation, toxin-mediated disease, and drug intoxication not previously available in the animal health market. VetResQ leverages a similar underlying blood purification technology in our commercialized CytoSorb® device that is approved in the European Union and has been used in more than 20,000 human treatments safely. Whether it is the sick thoroughbred racehorse or foal suffering from sepsis or toxic shock syndrome, a dog with acute pancreatitis in terrible pain, a cat after being struck by a car, or a dog poisoned from accidentally eating his owner’s pill bottles, the pathophysiology is remarkably similar to what is seen in humans, with a similar lack of available effective therapies. Our target customers are the large academic veterinary hospitals and veterinary practices where services like dialysis are administered.  Although this is a specialized niche market, we are providing this product at the request of many animal care providers and pet owners, with the goal of improving clinical outcomes for our most trusted and loved animal companions.”

VetResQ is capable of reducing a broad range of excessive inflammatory mediators and toxins that could otherwise cause direct tissue injury or serious systemic inflammation that can rapidly lead to instability, organ failure, and death. Some of the relevant substances VetResQ has been shown to remove include:

  • Excessive pro- and anti-inflammatory cytokines (Sepsis and SIRS – systemic inflammatory response syndrome)
  • Bacterial toxins such as Toxic shock syndrome toxin, Staph. aureus alpha-hemolysin, and fungal mycotoxins such as aflatoxin (Sepsis, infection)
  • Pancreatic enzymes (Severe acute pancreatitis)
  • Bilirubin  (Liver failure)
  • Myoglobin (Trauma)
  • Activated complement (Autoimmune diseases)
  • Lipophilic drugs (Accidental drug intoxication)

VetResQ is manufactured in the United States by CytoSorbents Corporation in three different sized cartridges (30mL, 100mL, and 300mL) for the treatment of cats, dogs, horses and animals of comparable size. VetResQ is compatible with standard hemodialysis, continuous renal replacement therapy (CRRT), and hemoperfusion blood pumps.  VetResQ is available only for veterinary animal usage and is not for human use.

For more information, please visit For pricing and to order, please contact Lea Garcia at [email protected]

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 20,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 31 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites at and or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact:
Amy Vogel

Investor Relations

(732) 398-5394

[email protected]

Public Relations Contact:

Amy Phillips
Pascale Communications
[email protected]



SOURCE CytoSorbents Corporation